Home / Press Releases / CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

TYSONS CORNER, VA, March 10, 2017 — A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday.

The company said Wednesday the designation enables DynPort Vaccine Company to receive incentives in its work to develop the recombinant rF1V vaccine as part of the Defense Department‘s medical countermeasure efforts against bioterrorism.

About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com

Contact:
David Smith
(703) 226-7002
david.smith@executivemosaic.com

Check Also

Roger Krone: Leidos Innovation Center, Dynetics to “Operate in Close Coordination”

TYSONS CORNER, VA, March 31, 2020 — Roger Krone, chairman and CEO of Leidos (NYSE: LDOS) and a recipient of the 2020 Wash100 award, has said the company will pair Dynetics with an innovation center that focuses on exploring emerging technology, ExecutiveBiz reported March 18.

Keith Johnson: Spire Provides Data Sets to Help Federal Clients Address Mission Challenges

TYSONS CORNER, VA, March 31, 2020 — Keith Johnson, vice president and general manager of Spire Global's federal business, said the company has embarked on data-driven projects that support the government's maritime domain awareness and transportation operations, ExecutiveBiz reported March 16.